As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround

As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround

Source: 
Xconomy
snippet: 

A decade ago, Kevin Conroy took the CEO job at Exact Sciences, a cancer diagnostic firm on the brink of death. Five years later, the FDA greenlit the company’s first product, Cologuard, which marked the first non-invasive, stool-based DNA screening test approved for detecting colorectal cancer.